Stentit: regenerating arteries without invasive surgery

March 22, 2022

“The idea of our regenerative stent was born in the laboratories of Technische Universiteit Eindhoven,” says Bart Sanders, CEO of STENTiT and one of our consortium partners. “Thanks to the growing regenerative medicine ecosystem that is developing in the region, there are resources and facilities to start up new businesses. We took advantage of that.” Sanders has learned about the obstacles before you can put a medical product on the market. “There are very strict controls for that. We must demonstrate that the stent is working properly and that the potential for negative consequences for the patient is minimal. The studies we must do to prove this are very expensive. It’s hard to get that money together. Investors are hesitant because they see it as a high risk. The further the product has been developed and tested, the smaller the risk for investors becomes.

But to achieve that, we need investments.” Fortunately, there is enough help, from different sides. As part of RegMed XB for example. Despite this, it is still difficult to raise sufficient funding at this stage, says Sanders. “It just takes a lot of money to really bring the product to market. We receive support from the Dutch government as well as the university.” Stentit is well on its way to the clinical trial phase and the ultimate goal is clear: “We started this company as two scientists with the question of how we as researchers can bring our idea to the patient. We really want to change patients’ lives.”

Connect with us